Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gouty Arthritis HELP
Based on 653 articles published since 2010

These are the 653 published articles about Arthritis, Gouty that originated from Worldwide during 2010-2020.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [S2e guidelines "Gouty arthritis - specialist"]. 2016

Kiltz, U / Braun, J. ·Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. Uta.Kiltz@elisabethgruppe.de. · Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. ·Z Rheumatol · Pubmed #27503463.

ABSTRACT: -- No abstract --

2 Guideline [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. 2016

Kiltz, U / Alten, R / Fleck, M / Krüger, K / Manger, B / Müller-Ladner, U / Nüßlein, H / Reuss-Borst, M / Schwarting, A / Schulze-Koops, H / Tausche, A / Braun, J. ·Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. uta.kiltz@elisabethgruppe.de. · Rheumatologie, Klinische Immunologie, Osteologie, Physikalische Therapie und Sportmedizin, Schlosspark-Klinik, Heubnerweg 2, 14059, Berlin, Deutschland. · Uniklinikum Regensburg, Klinik und Poliklinik für Innere Medizin I, Klinik für Rheumatologie/Klinische Immunologie, Asklepios-Klinikum, Kaiser-Karl-V.-Allee 3, 93077, Bad Abbach, Deutschland. · Rheumatologisches Praxiszentrum St. Bonifatius, St. Bonifatius Str. 5, 81541, München, Deutschland. · Medizinische Klinik 3, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland. · Abteilung für Rheumatologie und Klinische Immunologie, Kerckhoff-Klinik, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. · Rheumatologische Schwerpunktpraxis, Kontumazgarten 4, 90429, Nürnberg, Deutschland. · Facharzt-Praxis für Rheumatologie und Onkologie, Frankenstr. 36, 97708, Bad Bocklet, Deutschland. · Rheumatologisch-immunologische Ambulanz, Universitätsklinik Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland. · Klinikum der Universität München, Pettenkoferstr. 8a, 80336, München, Deutschland. · Medizinische Klinik III, Abteilung für Rheumatologie, Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74, 01307, Dresden, Deutschland. · Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. ·Z Rheumatol · Pubmed #27481119.

ABSTRACT: -- No abstract --

3 Guideline 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. 2012

Khanna, Dinesh / Khanna, Puja P / Fitzgerald, John D / Singh, Manjit K / Bae, Sangmee / Neogi, Tuhina / Pillinger, Michael H / Merill, Joan / Lee, Susan / Prakash, Shraddha / Kaldas, Marian / Gogia, Maneesh / Perez-Ruiz, Fernando / Taylor, Will / Lioté, Frédéric / Choi, Hyon / Singh, Jasvinder A / Dalbeth, Nicola / Kaplan, Sanford / Niyyar, Vandana / Jones, Danielle / Yarows, Steven A / Roessler, Blake / Kerr, Gail / King, Charles / Levy, Gerald / Furst, Daniel E / Edwards, N Lawrence / Mandell, Brian / Schumacher, H Ralph / Robbins, Mark / Wenger, Neil / Terkeltaub, Robert / Anonymous2340738. ·University of Michigan, Ann Arbor, MI, USA. ·Arthritis Care Res (Hoboken) · Pubmed #23024029.

ABSTRACT: -- No abstract --

4 Editorial Outcome measurement in acute gout: about constructs, perspectives, scales and timing. 2019

Vranken, Lieselot / Boonen, Annelies / Spaetgens, Bart. ·Department of Internal Medicine, Maastricht, The Netherlands. · Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands. · Care and Pubic Health Research Institute (CAPHRI), University Maastricht, Maastricht, The Netherlands. ·Rheumatology (Oxford) · Pubmed #31502647.

ABSTRACT: -- No abstract --

5 Editorial Ancient herbal component may be a novel therapeutic for gouty arthritis. 2019

Chen, Yibo / Chen, Xin. ·State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China. ·J Leukoc Biol · Pubmed #30517770.

ABSTRACT: -- No abstract --

6 Editorial PPARGC1B: insight into the expression of the gouty inflammation phenotype: PPARGC1B and gouty inflammation. 2017

Merriman, Tony / Terkeltaub, Robert. ·Department of Biochemistry, University of Otago, Dunedin, New Zealand. · VA San Diego Healthcare System. · Department of Medicine, University of California San Diego, San Diego, CA, USA. ·Rheumatology (Oxford) · Pubmed #28003496.

ABSTRACT: -- No abstract --

7 Editorial Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. 2017

FitzGerald, John D / Neogi, Tuhina / Choi, Hyon K. ·University of California, Los Angeles. · Boston University, Boston, Massachusetts. · Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ·Arthritis Rheumatol · Pubmed #28002890.

ABSTRACT: -- No abstract --

8 Editorial The Problem with Gout Is That It's Still Such a Problem. 2016

Coburn, Brian W / Mikuls, Ted R. ·Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center and the Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA; · Umbach Professor of Rheumatology, Department of Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center and the Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA tmikuls@unmc.edu. ·J Rheumatol · Pubmed #27481987.

ABSTRACT: -- No abstract --

9 Editorial Is the double contour sign specific for gout? Or only for crystal arthritis? 2015

Singh, Jasvinder A / Dalbeth, Nicola. ·Medicine Service, Birmingham VA Medical Center, Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health, University of Alabama, Birmingham, Alabama; and Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; · University of Auckland, and Auckland District Health Board, Auckland, New Zealand. ·J Rheumatol · Pubmed #25729038.

ABSTRACT: -- No abstract --

10 Editorial Gout, tophi and the wonders of NETs. 2014

Pisetsky, David S. · ·Arthritis Res Ther · Pubmed #25606589.

ABSTRACT: -- No abstract --

11 Editorial Crystal deposition diseases. 2014

Choi, Hyon. ·Boston University School of Medicine, Section of Rheumatology and the Clinical Epidemiology Unit, Boston, Massachusetts, USA. ·Curr Opin Rheumatol · Pubmed #24445481.

ABSTRACT: -- No abstract --

12 Editorial Duel energy CT imaging of tophaceous gout. 2013

Fitzgerald, L / Donnellan, J / Buckley, O / Kane, D. · ·Ir Med J · Pubmed #24282889.

ABSTRACT: -- No abstract --

13 Editorial ACTH analogues medications for the treatment of crystal-induced acute inflammation. A target to be explored? 2013

Perez-Ruiz, Fernando / Herrero-Beites, Ana María. · ·Joint Bone Spine · Pubmed #23522803.

ABSTRACT: -- No abstract --

14 Editorial Axial gout: cinderella of gouty arthropathy! 2012

Saketkoo, Lesley A / Garcia-Valladares, Ignacio / Espinoza, Luis R. · ·J Rheumatol · Pubmed #22753798.

ABSTRACT: -- No abstract --

15 Editorial T cells as key players for bone destruction in gouty arthritis? 2011

Harre, Ulrike / Derer, Anja / Schorn, Christine / Schett, Georg / Herrmann, Martin. · ·Arthritis Res Ther · Pubmed #22136246.

ABSTRACT: The deposition of monosodium urate (MSU) crystals in synovial fluid and tissue leads to gouty arthritis frequently associated with synovial inflammation and bone erosions. The cellular mechanism that links MSU crystals to an increased number of osteoclasts has not yet been fully understood. In a recent issue of Arthritis Research & Therapy Lee and colleagues proposed that bone destruction in chronic gouty arthritis is at least in part dependent on expression by T cells of receptor activator of NF-κB ligand (RANKL). The authors showed that pro-resorptive cytokines such as IL-1β, IL-6, and TNFα are expressed within tophi and stromal infiltrates. In vitro stimulation with MSU crystals revealed monocytes as a source for these cytokines, whereas T cells produce RANKL, the major trigger of osteoclastogenesis.

16 Editorial Can ultrasonography make identification of asymptomatic hyperuricemic individuals at risk for developing gouty arthritis more crystal clear? 2011

Schlesinger, Naomi. · ·Arthritis Res Ther · Pubmed #21542883.

ABSTRACT: Hyperuricemia is the most important risk factor for gouty arthritis. The quandary is how to predict which patient with asymptomatic hyperuricemia will develop gouty arthritis. Can ultrasonography help identify hyperuricemic individuals at risk for developing gouty arthritis? In the previous issue of Arthritis Research & Therapy, Pineda and colleagues found ultrasonography changes suggestive of gouty arthritis in 25% of hyperuricemic individuals. These were found exclusively in hyperuricemic individuals but not in normouricemic patients. Ultrasonography may serve as a noninvasive means to diagnose gouty arthritis in hyperuricemic individuals who have yet to develop symptomatic gouty arthritis.

17 Editorial Obesity and its complications. 2010

Okinda, N A. · ·East Afr Med J · Pubmed #23451553.

ABSTRACT: -- No abstract --

18 Editorial How interleukin-1β induces gouty arthritis. 2010

Dinarello, Charles A. · ·Arthritis Rheum · Pubmed #20662058.

ABSTRACT: -- No abstract --

19 Review Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis. 2020

Ristic, Bojana / Sikder, Mohd Omar Faruk / Bhutia, Yangzom D / Ganapathy, Vadivel. ·Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, United States. ·Asian J Pharm Sci · Pubmed #32373197.

ABSTRACT: Uric acid is the end product of purine catabolism and its plasma levels are maintained below its maximum solubility in water (6-7 mg/dl). The plasma levels are tightly regulated as the balance between the rate of production and the rate of excretion, the latter occurring in urine (kidney), bile (liver) and feces (intestinal tract). Reabsorption in kidney is also an important component of this process. Both excretion and reabsorption are mediated by specific transporters. Disruption of the balance between production and excretion leads to hyperuricemia, which increases the risk of uric acid crystallization as monosodium urate with subsequent deposition of the crystals in joints causing gouty arthritis. Loss-of-function mutations in the transporters that mediate uric acid excretion are associated with gout. The ATP-Binding Cassette exporter ABCG2 is important in uric acid excretion at all three sites: kidney (urine), liver (bile), and intestine (feces). Mutations in this transporter cause gout and these mutations occur at significant prevalence in general population. However, mutations that are most prevalent result only in partial loss of transport function. Therefore, if the expression of these partially defective transporters could be induced, the increased number of the transporter molecules would compensate for the mutation-associated decrease in transport function and hence increase uric acid excretion. As such, pharmacologic agents with ability to induce the expression of ABCG2 represent potentially a novel class of drugs for treatment of gouty arthritis.

20 Review Application of Chinese Medicine in Acute and Critical Medical Conditions. 2019

Luo, Yun / Wang, Chong-Zhi / Hesse-Fong, Julia / Lin, Jaung-Geng / Yuan, Chun-Su. ·Key Laboratory of Modern Preparation of Traditional Chinese Medicine, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, P. R. China. · Tang Center for Herbal Medicine Research, University of Chicago, Chicago, Illinois 60637, USA. · Department of Anesthesia and Critical Care, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA. · School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan. · Committee on Clinical Pharmacology and Pharmacogenomics, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA. ·Am J Chin Med · Pubmed #31505937.

ABSTRACT: Western medicine is routinely used in developed nations as well as in Eastern countries, where traditional medicine is frequently used by a selection of patients or family member as a complement to mainstream Western medicine. Chinese medicine plays an important role in the treatment of chronic diseases, especially when Western medicine is not very effective. Many published reports have shown that Chinese medicine could also be successfully used in the management of acute and critical illnesses. Chinese medicine has a holistic view of the human body, and emphasizes individualization based on body balance and mind-body interaction and employs herbal medicines and acupuncture. This review paper gives a brief overview of Chinese medicine theory and therapeutic modality and then addresses the application of Chinese medicine in the treatment of acute and critical medical conditions, including epidemics. Using this ancient therapy as a complementary medicine, the management of serious medical conditions, such as SARS, acute heart diseases, and ischemic cerebral stroke, are presented. In order to promote more widespread application of Chinese medicine, well-designed controlled clinical trials are urgently needed to prove its safety and effectiveness.

21 Review Can hyperuricemia predict glycogen storage disease (McArdle's disease) in rheumatology practice? (Myogenic hyperuricemia). 2019

Üsküdar Cansu, Döndü / Erdoğan, Bahattin / Korkmaz, Cengiz. ·Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, 26480, Eskişehir, Turkey. ducansu@hotmail.com. · Department of Pathology, Eskişehir City Hospital, Eskişehir, Turkey. · Division of Rheumatology, Department of Internal Medicine, Eskişehir Osmangazi University, 26480, Eskişehir, Turkey. ·Clin Rheumatol · Pubmed #31044384.

ABSTRACT: Gout disease is an inflammatory arthritis that arises due to the accumulation of monosodium urate crystals (MSU) around the joints and in tissues. Clinical manifestation of metabolic diseases leading to secondary hyperuricemia most predominantly occurs in the form of gouty arthritis. Hyperuricemia and gout may develop during the course of glycogen storage diseases (GSD), particularly in GSD type I, which involves the liver. On the other hand, during the course of GSD type V (GSDV, McArdle's disease), which merely affects the muscle tissue due to the deficiency of the enzyme myophosphorylase, hyperuricemia and/or gout is rarely an expected symptom. These patients may mistakenly be diagnosed as having idiopathic hyperuricemia and associated gout, leading to the underlying secondary causes be overlooked and thus, diagnostic delays may occur. In this case report, we present a premenopausal female patient who experienced flare-ups of chronic arthritis while on disease-modifying antirheumatic drugs and intraarticular steroids due to a diagnosis of undifferentiated arthritis. The patient was initially suspected of having gouty arthritis because elevated concentrations of uric acid were incidentally detected, but then, a diagnosis of asymptomatic GSDV was made owing to elevated concentrations of muscle enzymes during colchicine use. Our aims were to remind rheumatologists of the phenomenon of "myogenic hyperuricemia" and to discuss the potential causes of hyperuricemia that develop during GSD along with the available literature.

22 Review Painless gouty tophus in the nasal bridge: A case report and literature review. 2019

Chen, Shih-Lung / Chen, Jim-Ray / Yang, Shih-Wei. ·Department of Otolaryngology & Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou. · School of Medicine, Chang Gung University, Taoyuan. · Department of Pathology, Keelung Change Gung Memorial Hospital, Keelung. · Department of Otolaryngology & Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan. ·Medicine (Baltimore) · Pubmed #30882682.

ABSTRACT: RATIONALE: A gouty tophus, arising from the deposition of monosodium urate crystals (MSU), rarely occurs in the nasal bridge. There have been only 7 documented cases of a gouty tophus in the nasal bridge from 1978 to 2018 in English-language literature. PATIENT CONCERNS: A 65-year-old male had a chief complaint of a lump in the nasal bridge that was slowly growing for over 1 year. DIAGNOSIS: MSU crystals were confirmed through ultrasonography (US) and pathological examinations. INTERVENTIONS: A cosmetically less destructive method, ultrasound-guided fine needle aspiration cytology (FNAC) was used to approach the mass lesion of nasal bridge. OUTCOMES: The diagnosis was confirmed as a gouty tophus without performing a nasal subdermal exploration. LESSONS: This case report is the first use of US with FNAC to approach and diagnosed a gouty tophus in the nasal bridge.

23 Review Diagnostic advances in synovial fluid analysis and radiographic identification for crystalline arthritis. 2019

Zell, Monica / Zhang, Dawen / FitzGerald, John. · ·Curr Opin Rheumatol · Pubmed #30601230.

ABSTRACT: PURPOSE OF REVIEW: The present review addresses diagnostic methods for crystalline arthritis including synovial fluid analysis, ultrasound, and dual energy CT scan (DECT). RECENT FINDINGS: There are new technologies on the horizon to improve the ease, sensitivity, and specificity of synovial fluid analysis. Raman spectroscopy uses the spectral signature that results from a material's unique energy absorption and scatter for crystal identification. Lens-free microscopy directly images synovial fluid aspirate on to a complementary metal-oxide semiconductor chip, providing a high-resolution, wide field of view (∼20 mm) image. Raman spectroscopy and lens-free microscopy may provide additional benefit over compensated polarized light microscopy synovial fluid analysis by quantifying crystal density in synovial fluid samples. Ultrasound and DECT have good sensitivity and specificity for the identification of monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals. However, both have limitations in patients with recent onset gout and low urate burdens. SUMMARY: New technologies promise improved methods for detection of MSU and CPP crystals. At this time, limitations of these technologies do not replace the need for synovial fluid aspiration for confirmation of crystal detection. None of these technologies address the often concomitant indication to rule out infectious arthritis.

24 Review The Challenges of Approaching and Managing Gout. 2019

Fields, Theodore R. ·Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, Suite 848G, New York, NY 10021, USA. Electronic address: fieldst@hss.edu. ·Rheum Dis Clin North Am · Pubmed #30447743.

ABSTRACT: Despite many effective treatments for gout, its management remains a challenge internationally. Options for optimizing gout management may differ in different practice sizes and settings. Gout incidence is rising and it continues to be associated with increased mortality. Education of patients and medical providers is essential, and newer gout medications need to be used in the most appropriate ways for cost-effective therapy. Special consideration needs to be given to such populations as the elderly and those with renal and cardiovascular disease in gout management. New agents are in development, which may add to the armamentarium for gout management.

25 Review Crystallising the role of adrenocorticotrophic hormone in the management of acute gout: a review. 2019

Nisar, Muhammad K. ·Luton and Dunstable University Hospital NHSFT, Luton, UK. muhammad.nisar@ldh.nhs.uk. ·Clin Exp Rheumatol · Pubmed #30183601.

ABSTRACT: OBJECTIVES: Acute gout is traditionally treated with NSAIDs, corticosteroids, and colchicine. However, the presence of comorbid conditions and advancing age, often seen in hospitalised patients, may prevent their use. We reviewed the published data on the use of ACTH in the treatment of acute gouty arthritis. METHODS: A search was performed up to June 2017. We included clinical trials or case studies/series where ACTH had been administered in human subjects as a treatment for acute gout or pseudogout. RESULTS: Data consistently demonstrated ACTH to be fast-acting, typically relieving the painful symptoms of acute gout within 24 h of treatment. Furthermore, the average number of days needed to achieve 100% resolution of gout symptoms in patients treated with ACTH was similar to those of the corticosteroid triamcinolone. Retrospective data confirm the efficacy of ACTH or the synthetic analogue Synacthen in the treatment of acute gout in patients with comorbidities such as cardiovascular disease, chronic kidney disease, and hypertension, including those who were hospitalised, with all patients responding after 1-3 doses. ACTH appears to be well-tolerated with side effects being minor and transient in nature. Importantly, ACTH/Synacthen has no clinically significant effect on glucose and potassium levels or blood pressure. Clinical evidence from available case studies supports these findings. CONCLUSIONS: ACTH is a fast acting, efficacious and well-tolerated option for patients with acute gout when traditional therapies have failed or are contraindicated. However, large, carefully designed, randomised controlled trials are required to confirm these findings.